Menu
Several drugmakers recently announced refunds to 340B covered entities that purchased certain medications between 2020 and 2025.

Seven Drugmakers to Refund 340B Covered Entities for Overcharges, Organon Announces NDC Change for Biosimilar

Shannon Young, Associate Editor/Senior Writer 340B Report Views
Several drugmakers recently announced refunds to 340B covered entities that purchased certain medications between 2020 and 2025, following recalculations of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

Advanced 340B Operations for Maintaining Compliance during the Evolution of Technology

State Contract Pharmacy Lawsuit Roundup: Hearing and Filing on Maine’s Law, Update in Vermont

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live